Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting
21 Feb, 2019 | 04:01h | UTCDual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting – Journal of the American College of Cardiology (link to abstract – $ for full-text)
Commentaries: PRECISE-DAPT Score and Complex PCI – American College of Cardiology (free) AND After Stenting, Long-Term DAPT Benefits Those at Low Bleeding Risk More – NEJM Journal Watch (free)
Related Guidelines: 2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy (free) AND 2017 European Society of Cardiology focused update on dual antiplatelet therapy in coronary artery disease (free) AND 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease(free)
“Prospective studies are needed to verify whether patients at high bleeding risk derive net benefit from a shorter duration of DAPT after stenting, regardless of procedural complexity.” (from American College of Cardiology)
Related Commentary on Twitter
Patients undergoing complex PCI benefit of long DAPT only if high bleeding risk is not present (PRECISE-DAPT score <25), suggesting that when concordant, bleeding, more than ischemic risk, should inform DAPT duration. Full Results in @JACCJournals https://t.co/spfjRBvMdQ @vlgmrc pic.twitter.com/T1RT0n06QC
— Francesco Costa (@Costa_F_8) February 19, 2019